[Targeted molecular therapy and immunotherapy for prostate cancer]

Area of Science:

• Oncology
• Translational Research
• Genitourinary Cancers

Background:

• Advanced prostate cancer treatment historically focused on androgen receptor pathways and taxane chemotherapy.
• Recent translational research has introduced novel therapeutic strategies.
• Understanding homologous repair deficiency (HRD) has opened avenues for targeted treatments.

Purpose of the Study:

• To review the basic principles of new therapeutic innovations for advanced prostate cancer.
• To summarize the clinical development of emerging treatments.
• To highlight advancements beyond traditional therapies.

Main Methods:

• Review of recent clinical studies and translational research findings.
• Analysis of targeted therapies, including PARP inhibitors.
• Evaluation of immunotherapies such as checkpoint inhibitors and bispecific antibodies.
• Assessment of early-stage cellular therapies like CAR T-cells.

Main Results:

• PARP inhibitors demonstrate efficacy in selected patients with homologous repair deficiency (HRD), supported by positive Phase III trials.
• Immunotherapies, including checkpoint inhibitors and bispecific antibodies, exhibit clinically relevant activity in prostate cancer.
• Cellular therapies targeting prostate-specific membrane antigen (PSMA) are under early investigation.

Conclusions:

• Innovative therapies are expanding treatment options for advanced prostate cancer.
• Targeted therapies and immunotherapies represent significant progress.
• Further research is ongoing for cellular therapies and other novel approaches.